Sana’s Q4 2025 net loss widened year over year due to fair value adjustments, while research and development and general and administrative expenses declined following portfolio prioritization efforts.

Sana Biotechnology reported a Q2 2025 net loss of $93.8 million driven by impairment charges, while reducing operating expenses with non-GAAP results highlighting continued investment in R&D and cash runway into 2H 2026.

Sana Biotechnology reported a net loss of $49.4 million for the first quarter of 2025, a significant improvement compared to the $107.5 million loss in the same period last year. The company ended the quarter with $104.7 million in cash, cash equivalents, and marketable securities, with an expected cash runway into 2026. Sana highlighted positive clinical data for its type 1 diabetes program and progress in its allogeneic CAR T and in vivo CAR T pipelines.

Sana Biotechnology reported its Q3 2024 financial results, highlighting advancements in its hypoimmune technology across three clinical programs and five indications. The company increased its focus on type 1 diabetes and B-cell mediated autoimmune diseases, appointed a new Chief Scientific Officer, and anticipates data readouts in 2024 and 2025. Sana's cash position is $199.0 million, expected to fund operations into 2026.

Sana Biotechnology continues to advance its hypoimmune technology in four trials across seven indications. The company reported a cash position of $251.6 million and expects 2024 operating cash burn below $200 million.

Sana Biotechnology reported a net loss of $107.5 million for Q1 2024. The company completed a financing round of $189.8 million and has a cash position of $311.1 million. They are advancing four clinical programs and expect to share initial data from these studies in 2024.

Sana Biotechnology reported a net loss of $88.1 million for Q4 2023, with cash, cash equivalents, and marketable securities totaling $205.2 million. The company is advancing four clinical programs and expects to treat 40-60 patients across multiple indications in 2024.

Sana Biotechnology reported a net income of $1.0 million for Q3 2023, with a cash position of $268.6 million expected to last into 2025. The company is focused on developing its hypoimmune technology and anticipates data from multiple clinical settings in 2023 and 2024.

Sana Biotechnology reported its Q2 2023 financial results, highlighting the continued progress in their clinical programs, particularly the ARDENT trial for SC291 in B-cell malignancies, and the expectation of initial data from two clinical studies later in the year. The company's cash position is expected to support activities through multiple data readouts and last into 2025.

Sana Biotechnology reported a net loss of $82.1 million, or $0.43 per share, for the first quarter of 2023. The company's cash position was $355.1 million as of March 31, 2023, which is expected to support activities through multiple data readouts and last into 2025. The company is progressing with its clinical trials and expects data from two clinical studies in 2023.

Sana Biotechnology reported a Q4 2022 cash position of $434.0 million, with a runway into 2025. The company's first IND for SC291 was cleared, with initial clinical data expected this year. They also anticipate initial clinical data with hypoimmune islet cells in type 1 diabetic patients in 2023 and plan to file two INDs this year for SC262 and SG299.

Sana Biotechnology reported a net loss of $85.1 million for the third quarter of 2022. The company's cash position remains strong at $511.6 million, which is expected to fund operations into 2025. Key programs like SC291 and SG295 are progressing, with IND filings expected in the near future.

Sana Biotechnology reported a net loss of $72.5 million, or $0.39 per share, for the second quarter of 2022. The company's cash position was $579.6 million as of June 30, 2022, and they anticipate cash runway into 2025 due to cost savings from moving their manufacturing facility.

Sana Biotechnology reported a net loss of $31.4 million, or $0.17 per share, for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $657.4 million as of March 31, 2022. Significant progress was made towards clinical trials for programs across multiple platforms.

Sana Biotechnology reported a cash position of $746.9 million, research and development expenses of $108.5 million, and a net loss of $110.7 million for the fourth quarter of 2021. The company is progressing towards clinical trials for its multiple platforms and expects to file INDs for SC291 and SG295 in 2022.

Sana Biotechnology reported a net loss of $83.3 million, or $0.46 per share, for the third quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $866.1 million as of September 30, 2021. Sana also announced a license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.

Sana Biotechnology reported a net loss of $180.6 million, or $1.52 per share, for the three months ended March 31, 2021. The company's cash, cash equivalents, and marketable securities totaled $981.9 million as of March 31, 2021.

Sana Biotechnology reported a net loss of $113.2 million for the quarter ended December 31, 2020. The company's cash, cash equivalents, and marketable securities totaled $412.0 million as of December 31, 2020. Research and development expenses for the quarter were $104.1 million.